Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

Abroad (travel likely)Recruiting

Conditions

Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

MiraKind, Los Angeles, California, United States
Contact: Study coordinator (Joanne Weidhaas, MDPhD) · joanne@mirakind.org · 203-671-1308
Contact: Study coordinator (Joanne Weidhaas) · 424-387-8100

Study leads

Joanne Weidhaas, MDPhD
Principal Investigator
MiraKind

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Orange, United States · Skokie, United States

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

HER2-positive Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Bengbu, China · Fuyang, China

The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]

Small Cell Lung Cancers · Neuroendocrine Carcinoma

Abroad (travel likely)Recruiting

Incheon, South Korea · Seongnam, South Korea

Novel Body Composition Measurements in Association With Outcomes of Breast Reconstruction Reconstruction

Breast Carcinoma · Breast Cancer

Abroad (travel likely)Recruiting

San Francisco, United States